Inflammatory Bowel Diseases
30% of Inflammatory Bowel Disease patients relapse every year.1,2
30% of Inflammatory Bowel Disease (IBD) patients relapse every year.1,2 52% of Ulcerative Colitis (UC) patients who have an active disease are included in this statistic.1 An estimated 2.5 to 3 million people are affected by IBD in the EU.3 Current disease assessment techniques are suboptimal and do not accurately predict long term prognosis.4
Cellvizio® Clinical Value
With Cellvizio®, physicians predict relapse within the next 12 months, as well as major clinical events that require hospitalization or surgery for IBD patients.5,6
It also allows identification of residual colonic inflammation not detectable macroscopically in patients with IBD which in turn can help in determining the need for additional anti-inflammatory therapy and allows prediction of clinical outcomes.12
As a result, physicians are able to monitor treatment to differentiate responders from non-responders for UC patients.7
"Cellvizio® is the only technology that allows us to see functional healing, and it is worth having this information as it is the best determinant of outcome for my IBD patients"
Prof. Dr. T. Rath, University Hospital Erlangen
Cellvizio® mucosal assessment
using Cellvizio® ColoFlexTM UHD Miniprobe
Criteria: dark goblet cells, regular and narrow vessels surrounding crypts and round crypt structures
Criteria: mild to moderate increase of capillaries, dilated and distorted capillaries
Criteria: ridged-lined irregular epithelial layer with loss of crypts and goblet cells, Irregular cell architecture with little or no mucin
With Cellvizio®, patient management is improved because physicians can now differentiate between diagnoses of IBD (92% sensitivity, 91% specificity).8 They also can predict relapse and enable tailored biologic therapy to reduce IBD-related hospitalizations.9 During a flare period, mucosal inflammation is confirmed.10
The treatment improves because physicians can assess mucosal barrier function for predicting improved long-term patient outcomes for UC patients.7
In the case of cancer, physicians improve care by being able to characterize suspicious lesions.11
1. Data from Crohn’s & Colitis Foundation of America, 2014. https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated%20IBD%20Factbook.pdf
2. Bitton A. et al. Predicting relapse in Crohn’s disease: a biopsychosocial model. Gut, 2008.
3. Burisch J. et al. The burden of inflammatory bowel disease in Europe. Journal of Crohn’s and Colitis, 2013.
4. Liverani E. et al. How to predict clinical relapse in inflammatory bowel disease patients. World J Gastroenterol 2016
5. Turcotte JF. et al. Increased Epithelial Gaps in the Small Intestine Are Predictive of Hospitalization and Surgery in Patients With Inflammatory Bowel Disease, Clin tranfl Gastroenterol, 2012
6. Tontini GE. et al. Prediction of clinical outcomes in Crohn’s disease by using confocal laser endomicroscopy: results from a prospective multicenter study. Gastrointestinal Endoscopy. 2017
7. Hundorfean G. et al. Development and Validation of a Confocal Laser Endomicroscopy-Based Score for In Vivo Assessment of Mucosal Healing in Ulcerative Colitis Patients. Inflamm Bowel Dis, 2017.
8. Queneherve L. et al. Quantitative assessment of mucosal architecture using computer-based analysis of confocal laser endomicroscopy in inflammatory bowel diseases. Gastrointest Endosc, (Epub), 2018.
9. Liu J. et al. Personalized Inflammatory Bowel Disease Care Reduced Hospitalizations. Digestive Diseases and Sciences, 2019.
10. Maione F. et al. Confocal laser endomicroscopy in ulcerative colitis: beyond endoscopic assessment of disease activity. Tech Coloproctol, (Epub), 2017
11. Lord R. et al. Colonic lesion characterization in inflammatory bowel disease: A systematic review and metaanalysis. World J Gastroenterol, 2018.
12. Al-Mansour. et al. SAGES TAVAC safety and efficacy analysis confocal laser endomicroscopy. Surg Endosc, 2020.